
© Amir Cohen / Reuters In an 18-8 vote, the joint panel concluded the benefits of Opana ER did not outweigh the risks. Among people who reported abusing Opana, the percentage who injected it roughly doubled after the reformulation, from 17 percent to 38 percent.
Opana ER, an opioid painkiller redesigned in 2012, still carries too high a risk of abuse despite its potential health benefits, said a joint Food and Drug Administration advisory panel. Despite its reformulation, drug users began using it intravenously.
The 27 voting members from the Drug Safety and Risk Management (DSaRM) and Anesthetic and Analgesic Drug Products (AADP) advisory committees had to evaluate Opana ER's safety compared to other products, its risk-benefit profile, and possible consequences to patients if the FDA imposed regulatory action on the drug.
In an 18-8 vote, the joint panel concluded the benefits of Opana ER did not outweigh the risks. One member abstained from voting.
"It seems clear that the abuse-deterrent characteristics of the produce have resulted in unintended consequences," said Jane Acri, chief of medications discovery and toxicology branch at the National Institute of Drug Abuse (NIDA), according to NPR. The drug was one of several opioids available for the treatment of chronic pain, so there were alternatives, Acri said.
Comment: It's entirely possible that both lab tests are accurate. There could have easily been a lot of chicken which got too much filler and that was the one tested, or the chicken provided to Subway's labs was knowingly of a higher quality than that you get in their stores. A lot of possible explanations, but at the end of the day our readers should know that fast-food is never a good choice for your health.